Why chemotherapy that costs $70,000 in the U.S. costs $2,500 in India
Why does Gleevec, a leukemia drug that costs $70,000 per year in the United States, cost just $2,500 in India? It's seemingly simple. Gleevec is under patent in the U.S., but not in India. Accordingly, Novartis, its Swiss-based manufacturer, may prevent competitors from making and selling lower-cost versions of the drug in the U.S., but not in India. Last week, India's highest court rejected an application to patent Gleevec. While the legal issue in the case is important -- the patentability of modifications to existing drugs under Indian law -- the impact of the decision will likely be broader than just that issue, escalating a long-simmering fight over patented cancer medications in emerging markets.
- Governors Push to Expand Role of PAs, Telemedicine
- 3 More Pioneer ACOs Say They Will Quit
- Telemetry Overuse Cost Health System $4.8 Million in One Year
- Why Open Payments Irks Physicians
- Ebola in the U.S.: Reason to Fear, to Hope, to Prepare
- IV Fluids Shortage Continues
- Difficult Patients: It's Not Them, It's You, Doctor
- Overcoming a Payer Mix 'Nightmare'
- Employee Engagement: Make It Meaningful
- Proton Beam Therapy Center Closure Illuminates Costs